Global healthcare company Schering-Plough announced on Monday that it has completed its acquisition of Organon BioSciences.
Organon BioSciences, which is comprised mainly of a human health business (Organon) and an animal health business (Intervet), was purchased by Schering-Plough from the Dutch Akzo Nobel NV for a sum of €11b.
The global animal health business of the company will be based in Boxmeer, The Netherlands.
Through this transaction, Schering-Plough will become the global leader in animal health. Fred Hassan, chairman and chief executive officer, commented that the fusion will “bring added value to the customers. This combined animal health unit is strategically a key business, which will contribute to our long-term high performance”.
For the animal health industry, the combination of these two large pharmaceutical and vaccine producers creates a strong platform to help prevent and cure diseases.
Schering will now acquire additional vaccines such as VISTA/BOVILIS which target respiratory and reproductive infectious diseases in cattle. Antiparasitics will be added to the existing product portfolio such as SAFE-GUARD/PANACUR, a de-wormer for many animal species along with a number of other animal health preparations.